Kyverna Therapeutics announced positive 12-month topline results from two trials for its miv-cel cell therapy in stiff-person syndrome and generalized myasthenia gravis. The data indicates strong, durable efficacy and a favorable safety profile, positioning the company for a Biologics License Application submission.
Kyverna Therapeutics reported significant positive 12-month data for its miv-cel cell therapy in two rare neurological conditions, stiff-person syndrome and generalized myasthenia gravis. This is a major positive development for the company as it demonstrates the therapy's durable efficacy and safety, which are crucial for regulatory approval. The company is on track to submit its Biologics License Application in Q4 2026 for stiff-person syndrome, and expects to complete enrollment for the Phase 3 gMG study in mid-2027. This news could lead to increased investor confidence and potential stock appreciation for KYTX in the short to medium term, as it de-risks the development pathway for a potentially blockbuster drug. The long-term implications depend on successful regulatory approval and commercialization.